A phase I trial of the pan-ERBB inhibitor neratinib combined with the MEK inhibitor trametinib in patients with advanced cancer with EGFR mutation/amplification, HER2 mutation/amplification, HER3/4 mutation or KRAS mutation.

Sarina A Piha-PaulChieh TsengHai T TranMeng GaoDaniel D KarpVivek SubbiahApostolia Maria TsimberidouJitesh D KawediaSiqing FuShubham PantTimothy A YapVan K MorrisBryan K KeeMariela Blum MurphyJoAnn LimFunda Meric-Bernstam

Published in: Cancer chemotherapy and pharmacology (2023)

NCT03065387.

Keyphrases

advanced cancer
small cell lung cancer
palliative care
tyrosine kinase
clinical trial
study protocol
cell proliferation
epidermal growth factor receptor
phase iii
label free
pi k akt
phase ii